

renal function. Eculizumab is a potent drug that can act even though in stage 5 kidney failure. Although re-biopsy could not be performed because of thrombocytopenia, treatment with eculizumab improved her renal function, including with long standing fibrotic changes.

In conclusion, we present a patient who was initially admitted with nephritic syndrome and C3G was diagnosed and immunosuppressive treatment was initiated, two months later after diagnosis she was re-admitted with thrombotic microangiopathy and aHUS was diagnosed. After administration of eight month of eculizumab therapy her residual renal clearance improved and her dialysis treatment was further reduced to once a week. The present case report demonstrated a CFI genetic variation associated alternative pathway dysregulation causing C3G and aHUS in the same patient and highlighted the shared pathogenesis in these alternative complement pathway associated diseases.

Acknowledgments

The authors declare that they have no sources of funding for this study, and they have no conflicts of interest to declare.

REFERENCES

1. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. *Kidney Int.* 2017;91:539–51.
2. Goicoechea de Jorge E, Caesar JJ, Malik TH, Patel M, Colledge M, Johnson S, et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo. *Proc Natl Acad Sci U S A.* 2013;110:4685.
3. Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. *Lancet.* 2010;376:794.
4. McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. *Am J Transplant.* 2012;12:1046.
5. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. *N Engl J Med.* 2012;366:1161.
6. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. *N Engl J Med.* 2012;366:1163.

Muge Catikkas^a, Erol Demir^{a,*}, Yasemin Ozluk^b,
Yasar Caliskan^a, Rabia Muberra Badur^a, Aydin Turkmen^a

^a Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

^b Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

* Corresponding author.

E-mail address: eroldemir83@yahoo.com (E. Demir).

2013-2514/© 2018 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).
<https://doi.org/10.1016/j.nefro.2018.04.001>

Low rate of adverse events in home hemodialysis[☆]

Baja tasa de eventos adversos en hemodiálisis domiciliaria

Dear Editor,

Currently due to the benefits reported with HHD,^{2,3} there is growing interest in home haemodialysis (HHD).¹ In Spain, although the number of patients on HHD has increased in recent years, the percentage remains low,¹ one of the main problems being that there is little familiarity with the technique⁴ and the fear of adverse events (AE) is manifested. For this reason, we considered it appropriate to analyse the AEs observed in the HHD unit of our Hospital from the beginning of the programme in March 2008 until June 2017.

We consider a serious adverse event (SAE) the one that required some type of emergency action by medical

professionals, being automatically reported by the patient to the hospital, usually over the phone. Minor adverse events (MAE) were recorded by the patient in the haemodialysis form, and we conducted a retrospective analysis of these.

Since the HHD programme was started, we have trained 35 patients, 32 were able to move home and 3 did not pass the training (2 patients lacked self confidence and one had associated comorbidity).

Of the 32 patients on HHD: average age 57.6 ± 13.1 years; Charlson index 4.1 ± 1.7; 18 men, 14 women, 25% with diabetes mellitus.

Haemodialysis (HD) time/session was 149.5 ± 16.1 min; frequency 5.3 ± 0.5 sessions/week; weekly time 791.9 ± 94.8 min;

DOI of original article:

<https://doi.org/10.1016/j.nefro.2017.09.009>.

* Please cite this article as: Pérez Alba A, Reque Santiváñez J, Segarra Pedro A, Torres Campos S, Sánchez Canel JJ, Fenollosa Segarra MÁ, et al. Baja tasa de eventos adversos en hemodiálisis domiciliaria. *Nefrología.* 2018;38:452–454.




Fig. 1 – Percentage of minor adverse events.

14 NxStage systems and 18 conventional monitors; 20,034 days remaining at home (17,889 days/catheter and 2145 days/fistula).

In total, 4 SAEs, 0.072 events/patient/year (0.275 SAEs/1000 HD sessions).

Two episodes occurred in the same 49-year-old patient, after 7 and 9 months on HHD. The first was hypotension with loss of consciousness and recovery after being disconnected by the carer, who called the emergency services and the patient was transferred to hospital without requiring admission. The second episode was a new hypotensive episode with loss of consciousness and seizure, with the carer again being present. Hospitalisation was required to rule out the possibility that the patient had stopped taking antiepileptic medication. In both cases, the patient was ultrafiltrating a greater quantity than recommended by our unit.

The third episode occurred in a 43-year-old patient who had been on HHD for less than 6 months. It was a clot in the circuit at the end of the HD session, which reached the tunneled catheter, causing full obstruction thereof. The patient was transferred to hospital where we removed the obstruction with urokinase and the patient was not admitted.

The fourth episode was a new hypotensive episode in a 72-year-old patient, without loss of consciousness, but a call

to the emergency services was required without transfer to hospital.

Regarding the MAEs, we retrospectively analysed 11,463 haemodialysis sessions (78.9% of the total HHD completed). In the remaining cases it was impossible for us to recover the information. We recorded 272 MAEs (Fig. 1), with a MAE rate of 23.72/1000 HD sessions.

Forty-one hospitalisations occurred (24.4% scheduled), 0.747 admissions/patients/year (19.5% due to cardiovascular causes, 26.8% due to infectious causes not related to vascular access, and 12.2% due to infectious causes related to vascular access). Six infection events related to the haemodialysis catheter, 5 required hospital admission (0.12 infections/patient/year) and none in the arteriovenous fistula. Regarding vascular access dysfunctions recorded as such by the patient on HHD sheets, 16 were due to catheter (1.59/1000 HD, 8 required hospital HD), 13 were due to fistula (8.95/1000 HD, 10 required hospital HD), relative risk 5.6 (2.7–11.6).

We did not record significant differences when we attempted to relate the MAE rates to patient age, Charlson [index], number of training sessions, and type of monitor used.

Patients required HD in a hospital unit, without considering admission episodes, for 454 days (Table 1).

Table 1 – Outpatient HD needs at hospital unit.

Reason	No. of frequency	Percentage of frequency	Days	Percentage of days	Average no. of days	Range of days
Vascular access problem	19	38.77	74	16.29	1	1–30
Puncture training	3	6.12	149	32.81	14	12–123
Monitor problem	8	16.32	8	1.76	1	–
Water problem	6	12.24	12	2.64	1	1–7
Monitor replacement	1	2.04	30	6.6	30	–
Other	12	24.48	181	39.86	8	1–41

HD: haemodialysis.

We present a SAE rate similar to those described in the few existing series in the medical literature,^{5,6} although it depends what is considered as such, while Wong et al.⁵ describe it as a life-threatening event, Tennankore et al.⁶ consider it, like we did, as one requiring some kind of medical action. As for MAEs, data are also limited,^{7,8} again depending on what is considered a minor event, but our report is similar to previous publications.

We consider that in each HHD unit there should be an ongoing record of AEs that occur,⁹ if possible in real time, in order to establish the control and feedback methods for said events, to generate strategies and action protocols in order to minimise them. In our case, we set lower ultrafiltration limits, always at 10 ml/kg/h. The exploration of the possibilities offered by telemedicine can provide great assistance in this regard.¹⁰

Furthermore, in all HHD units there should also be a series of dialysis stations that ensure sessions are available at times when the patient cannot do it at home.

We conclude that, despite being impossible to eradicate the possibility of AEs, the rate thereof is more than acceptable, making HHD a safe technique that can offer many benefits to patients.

REFERENCES

- Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A, et al. US renal data system 2013 annual data report. *Am J Kidney Dis.* 2014;63 Suppl. 1:A7.
- Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, et al. In-center hemodialysis six times per week versus three times per week. *N Engl J Med.* 2010;363:2287-300.
- Nesrallah GE, Lindsay RM, Cuerden MS, Garg AX, Port F, Austin PC, et al. Intensive hemodialysis associates with improved survival compared with conventional hemodialysis. *J Am Soc Nephrol.* 2012;23:696-705.
- Agar JW, Schatell D, Walker R. Home hemodialysis needs you! *Hemodial Int.* 2015;19 Suppl. 1:S4-7.

- Wong B, Zimmerman D, Reintjes F, Courtney M, Klarenbach S, Dowling G, et al. Procedure-related serious adverse events among home hemodialysis patients: a quality assurance perspective. *Am J Kidney Dis.* 2014;63:251-8.
- Tennankore KK, d'Gama C, Faratro R, Fung S, Wong E, Chan CT. Adverse technical events in home hemodialysis. *Am J Kidney Dis.* 2015;65:116-21.
- Kraus M, Burkart J, Hegeman R, Solomon R, Coplon N, Moran J. A comparison of center-based vs. home-based daily hemodialysis for patients with end-stage renal disease. *Hemodial Int.* 2007;11:468-77.
- Sands JJ, Lacson E Jr, Ofsthun NJ, Kay JC, Diaz-Buxo JA. Home hemodialysis: a comparison of in-center and home hemodialysis therapy in a cohort of successful home hemodialysis patients. *ASAIO J.* 2009;55:361-8.
- Pauly RP, Eastwood DO, Marshall MR. Patient safety in home hemodialysis: quality assurance and serious adverse events in the home setting. *Hemodial Int.* 2015;19 Suppl. 1: S59-70.
- Chow J, Donaldson P, Fortnum D, Frasca S, Grimley K, Hyde C, et al. Beyond dialysis. Telehealth initiatives. *RSAJ.* 2016;12:18-25.

Alejandro Pérez Alba*, Javier Reque Santiviáñez, Alba Segarra Pedro, Silvia Torres Campos, Juan José Sánchez Canel, M. Ángeles Fenollosa Segarra, Ramón Pons Prades

Hospital General de Castellón, Castellón de la Plana, Castellón, Spain

* Corresponding author.

E-mail address: aperezalba@gmail.com (A. Pérez Alba).

2013-2514/© 2017 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<https://doi.org/10.1016/j.nefro.2018.04.007>

Juxtaanastomotic venous aneurysms in arteriovenous fistulas for hemodialysis[☆]

Aneurismas venosos yuxtaanastomóticos en fístulas arteriovenosas para hemodiálisis

Dear Editor,

Venous aneurysms in the arteriovenous fistulas (AVF) are common, between 5% and 60% according to the series and the

definition of aneurysm being used.¹⁻³ In the majority of cases there is secondary weakness in the vessel wall due to repeated punctures. They are true dilations of the vessel, which conserves all its layers, unlike pseudoaneurysms, in which a rupture of the vascular wall.

DOI of original article:

<https://doi.org/10.1016/j.nefro.2017.09.007>.

* Please cite this article as: Jiménez-Almonacid P, Pila U, Gruss E, Lasala M, Rueda JA, Colás E, et al. Aneurismas venosos yuxtaanastomóticos en fístulas arteriovenosas para hemodiálisis. *Nefrología.* 2018;38:454-457.